Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
elacestrant save search
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Published: 2023-09-20 (Crawled : 15:00) - prnewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 0.07%
H: 2.72%
C: -0.85%
orserdu breast cancer treatment her2-
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2
Published: 2023-07-21 (Crawled : 13:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 0.21%
H: 0.67%
C: -0.98%
orserdu chmp her2 approval positive group treatment
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
Published: 2023-05-26 (Crawled : 11:00) - prnewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 0.87%
H: 0.69%
C: -0.27%
orserdu breast asco cancer group study
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -0.29%
H: 1.97%
C: 0.62%
elacestrant breast asco cancer group meeting
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $1.385 -0.36% -0.36% 46K
|
Health Technology
|
| O: 78.62%
H: 27.05%
C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2- her2
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval therapeutics cancer orserdutm elacestrant esr1 mutation elascestrant her2- her2 metastatic breast cancer
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 12:20) - prnewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval cancer orserdutm elacestrant esr1 mutation elascestrant her2- her2 metastatic breast cancer
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 12:20) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval therapeutics cancer elacestrant esr1 mutation elascestrant orserdu her2- her2 metastatic breast cancer
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Published: 2022-08-11 (Crawled : 10:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 1.59%
H: 2.25%
C: -0.08%
fda elacestrant granted review cancer elascestrant her2- her2 metastatic breast cancer
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Published: 2022-06-22 (Crawled : 21:00) - globenewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 0.39%
H: 1.01%
C: -3.47%
fda elacestrant drug health application group elascestrant
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - ir.radiuspharm.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 1.01%
H: 4.6%
C: 0.92%
elacestrant trial group phase 3 elascestrant
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-19 (Crawled : 16:20) - ir.radiuspharm.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3 elascestrant
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3 elascestrant
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
Published: 2021-12-08 (Crawled : 15:30) - globenewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -39.56%
H: 8.61%
C: -7.84%
elacestrant trial trial results positive results cancer breast cancer symposium elascestrant
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: 36.48%
H: 9.0%
C: -14.74%
positive results cancer topline elacestrant phase 3 breast cancer trial elascestrant
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.